Nuclea Biotechnologies

Headed by Nuclea's former Founder and CEO Patrick Muraca, NanoMolecular aims to commercialize cancer diagnostics including Nuclea's Her2/neu assay.

Nuclea's trustee has requested the court approve sale of its assets, which failed to sell at auction, to a firm run by Nuclea's former CEO Patrick Muraca.

Set for Jan. 18, 2017, the sale will feature assets including its HER-2/neu assay, a blood-based test for monitoring women with metastatic breast cancer.

Under the partnership the two companies will develop assays for insulin, proinsulin, and c-peptide on clinical sample cohorts at both Nuclea and IRCM's facilities.

The company will focus largely on applying mass spec to relatively established protein markers for which existing immunoassay-based tests have poor performance.

The arrangement will join Nuclea's expertise in proteomics with Aelan's genomics know-how.

The firm is now clinically validating a mass spec-based test for quantifying native insulin and its therapeutic analogs and another test for type 2 diabetes. 

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific and Nuclea Biotechnologies said this week they are collaborating on mass spec-based assays for quantification of native insulin and its therapeutic analogs.

NEW YORK (GenomeWeb News) – Nuclea Biotechnologies and Thermo Fisher Scientific said today that they are collaborating on multiplexed mass spec assays for quantifying native insulin and its therapeutic analogs.

NEW YORK (GenomeWeb) – Nuclea Biotechnologies today said it has inked an agreement with Clinical Reference Laboratory to validate three of Nuclea's tests.

Pages

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.